Immediate Impact
60 standout
Citing Papers
Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders
2024 Standout
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
Works of Franck Rouby being referenced
Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
2020
Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Franck Rouby | 207 | 73 | 12 | 85 | 18 | 351 | |
| Paul Zorsky | 201 | 36 | 4 | 52 | 16 | 388 | |
| S Costantini | 117 | 72 | 6 | 58 | 19 | 370 | |
| Olga Bessmertny | 55 | 37 | 10 | 87 | 17 | 357 | |
| Myke R. Green | 150 | 54 | 47 | 47 | 22 | 384 | |
| Yinghong Zhai | 122 | 26 | 16 | 46 | 20 | 315 | |
| Friso L. H. Muntinghe | 112 | 53 | 5 | 63 | 18 | 397 | |
| L. Bigay-Gamé | 119 | 26 | 9 | 184 | 31 | 325 | |
| Ali Yılmaz | 225 | 25 | 5 | 73 | 24 | 314 | |
| Snehal G. Thakkar | 137 | 34 | 1 | 197 | 18 | 411 | |
| Erica Linden | 113 | 30 | 5 | 68 | 12 | 357 |
All Works
Loading papers...